March 3 (Reuters) - ACADIA Pharmaceuticals Inc ACAD.O:
ACADIA PHARMACEUTICALS AND SANIONA ANNOUNCE INITIAL POSITIVE RESULTS FROM ACP-711 (FORMERLY SAN711) PHASE 1 STUDY
IN STUDY, ACP-711 WAS SAFE AND GENERALLY WELL TOLERATED ACROSS ALL DOSING COHORTS
THERE WERE NO SERIOUS ADVERSE EVENTS
NO SAFETY LABORATORY CONCERNS, CARDIOVASCULAR CONCERNS, OR ABNORMAL NEUROLOGICAL FINDINGS WERE OBSERVED
Source text: ID:nMFN6HH2Qx
Further company coverage: ACAD.O
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.